Session » Vasculitis – Non-ANCA-Associated & Related Disorders Poster III

Date: Monday, November 18, 2024

Time: 10:30AM-12:30PM

Meeting: ACR Convergence 2024

10:30AM-12:30PM: Abstract Number: 2522

Anticoagulant Treatment May Decrease the Relapse Rate in Pulmonary Arterial Involvement of Behçet’s Disease When Added After the First Event

10:30AM-12:30PM: Abstract Number: 2518

Behçet’s Disease Immune Landscape Exhibits a Universal NF-kB-mediated Hyperactivation Pattern with Cell-specific TNFAIP3 Responses and a Superimposed IFN-regulated Endotype

10:30AM-12:30PM: Abstract Number: 2523

Biological Treatment May Be an Option as First Steroid-Sparing Agent in a Subgroup of Young Takayasu Arteritis Patients with Prominent Acute Phase Reactants and Constitutional Symptoms

10:30AM-12:30PM: Abstract Number: 2509

Bone Marrow Failure in VEXAS Is Associated with the Degree of UBA1b Deficiency

10:30AM-12:30PM: Abstract Number: 2505

C5 Signaling Pathway Genes as Key Drivers of the Pathogenesis of IgA Vasculitis?

10:30AM-12:30PM: Abstract Number: 2525

Challenges and Opportunities in Integrating Sleep Recommendations into Counselling Patients with Arthritis: A Survey of Physical Therapists and Physical Therapy Students

10:30AM-12:30PM: Abstract Number: 2502

Characterization of the Tissue Fibroblast Repertoire in IgG4-Related Ophthalmic Disease

10:30AM-12:30PM: Abstract Number: 2511

Clinical Characteristics and Outcomes of Patients with Clinically Isolated Aortitis

10:30AM-12:30PM: Abstract Number: 2521

Clinicopathologic Associations Between Macrophage Location and Functional Profile in Giant Cell Arteritis

10:30AM-12:30PM: Abstract Number: 2499

Description of Patients with Kawasaki Disease Shock Syndrome at a Large Tertiary Center

10:30AM-12:30PM: Abstract Number: 2500

Description of Patients with Refractory Kawasaki Disease at a Large Tertiary Center

10:30AM-12:30PM: Abstract Number: 2526

Development of the Hospital Emergency Advocacy & Treatment Kit (HEAT Kit) for Patients with Vasculitis

10:30AM-12:30PM: Abstract Number: 2516

Exome-Wide Rare Variant Association Study of Takayasu’s Arteritis

10:30AM-12:30PM: Abstract Number: 2512

French Multicenter Retrospective Study of Patients with Cocaine- and/or Levamisole-induced Vasculitis and Vasculopathy

10:30AM-12:30PM: Abstract Number: 2513

Frequency, Diagnosis, and Management of Polymyalgia Rheumatica in Germany – Database Analysis of Medical Insurance Data

10:30AM-12:30PM: Abstract Number: 2503

Hypothalamic-Pituitary-Adrenal Axis Suppression by Prednisolone Reversed by the 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibitor Clofutriben

10:30AM-12:30PM: Abstract Number: 2507

IgG4-related Disease Features and Immunological Profile in a Tertiary Center in Sao Paulo-Brazil

10:30AM-12:30PM: Abstract Number: 2501

Long-term Remission off Therapy (LTROT) Is Possible in Non-infectious Aortitis with DMARDs with Low Risk of Secondary Adrenal Insufficiency

10:30AM-12:30PM: Abstract Number: 2524

Metabolite Profiling of Saliva for the Discrimination of Behcet’s Disease, Sjogren’s Syndrome, and Recurrent Aphthous Stomatitis

10:30AM-12:30PM: Abstract Number: 2504

Polyarteritis Nodosa Associated with VEXAS Syndrome and Chronic Myelomonocytic Leukemia Compared with Primary Forms: A Case-Control Study

10:30AM-12:30PM: Abstract Number: 2520

Prevalence and Incidence of Giant Cell Arteritis Among Medicare Fee-For-Service Beneficiaries: United States, 2014–2019

10:30AM-12:30PM: Abstract Number: 2517

Skin Microbiome Shows Differences Between Pathergy Positive and Negative Patients with Behçet’s Syndrome

10:30AM-12:30PM: Abstract Number: 2510

The Effect of Coronary Artery Aneurysms and IVIG Use on Long-term Cardiovascular Disease and Mortality Following Kawasaki Disease in Childhood: A Systematic Review and Meta-analysis

10:30AM-12:30PM: Abstract Number: 2508

The Impact of Lipid Profile Parameters on the Incidence of Major Adverse Cardiovascular Events in Rheumatoid Arthritis Patients: A Single-arm Meta-Analysis

10:30AM-12:30PM: Abstract Number: 2498

The Methylome Profile of B-cells as a Biomarker of Nephritis in IgA Vasculitis

10:30AM-12:30PM: Abstract Number: 2514

The Pattern of Renal Involvement in Relapsing Cryoglobulinemic Vasculitis After Successful Sustained Viral Response by Direct-Acting Antiviral Treatments

10:30AM-12:30PM: Abstract Number: 2506

THP1-derived Macrophage Polarization in Takayasu Arteritis – Impact of Disease Status and Therapy

10:30AM-12:30PM: Abstract Number: 2515

Upadacitinib for Refractory Behçet’s Syndrome: A Multi-center, Prospective, Open-label, Pilot Study

10:30AM-12:30PM: Abstract Number: 2519

What Do We Know About Malignancies in IgA Vasculitis?

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].